Annotation Detail

Information
Associated Genes
BRCA1
Associated Variants
BRCA1 LOSS-OF-FUNCTION
BRCA1 LOSS-OF-FUNCTION
Associated Disease
breast cancer
Source Database
CIViC Evidence
Description
Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2–negative metastatic breast cancer. 205 patients were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio 0.58; 95%CI 0.43 to 0.80; P<0.001). A response to treatment occurred in 100 of the 167 patients who had measurable disease in the olaparib group (59.9%; 95% CI, 52.0 to 67.4) and in 19 of the 66 patients in the standard-therapy group (28.8%; 95% CI, 18.3 to 41.3). A complete response was seen in 9.0% of the patients who had measurable disease in the olaparib group and in 1.5% in the standard-therapy group.
Variant Origin
germline
Variant Origin
Rare Germline
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/5830
Gene URL
https://civic.genome.wustl.edu/links/genes/6
Variant URL
https://civic.genome.wustl.edu/links/variants/185
Rating
4
Evidence Type
Predictive
Disease
Breast Cancer
Evidence Direction
Supports
Drug
Olaparib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
28792849
Drugs
Drug NameSensitivitySupported
OlaparibSensitivitytrue